Back to Stocks

MDT

Medtronic plc
2 filings tracked
healthcaremedical devicesLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The investment narrative has shifted from a broad-based medical device play to a focused bet on high-margin, AI-integrated healthcare technology.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Conversely, the bear case has evolved from simple margin concerns to a critique of the company's capital allocation and risk management.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MDT filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Medtronic's latest filing marks a pivotal transition as the company completes the strategic separation of its Diabetes Business in March 2026.…

Latest Available Quarter (Q2 '26 (10-K))

Core Takeaway

Not specified.

Investor Lens

Not specified.

Watch Next

Not specified.

Calculated Financial Trajectory (Click to filter signals)

Revenue (M)$19,500
FY '26: $19,500
Net Income (M)$1,200
FY '26: $1,200
Gross Margin (%)43.5
FY '26: 43.5
Net Debt (M)$15,000
FY '26: $15,000

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.15Q1 '26 (10-Q)0.00Q2 '26 (10-K)

Signal Timeline

bullishJun 18

Completed separation of Diabetes Business to focus on high-margin segments.

divestiture
90%
bearishJun 18

Significant debt maturities in 2026 and 2029 create refinancing risk.

debt restructure
80%
bearishJun 18

Ongoing antitrust and product liability litigation with unquantified exposures.

regulatory action
70%
bullishJun 18

Operating profit increased to $6.5 billion as the company pivots to AI.

margin expansion
60%
bullishFeb 24

Planned separation of the Diabetes business into MiniMed Group, Inc.

divestiture
90%
bearishFeb 24

Cost of products sold is rising significantly faster than revenue.

margin compression
80%
neutralFeb 24

Issued $1.75 billion in new senior notes to manage liquidity.

debt restructure
60%
bearishFeb 24

Operating income declined 11.1% year-over-year.

earnings miss
70%

Filing History

10-KJun 18, 2026
Expand Sequence

The fiscal 2026 10-K reveals a company in the midst of a high-stakes identity shift. Medtronic is successfully streamlining its operational footprint through the divestiture of its diabetes business, but it is doing so while managing a heavy debt load and significant regulatory headwinds. The tension between its cutting-edge AI ambitions and its legacy financial obligations defines the current investment profile. Ultimately, the filing suggests that Medtronic's success depends on whether margin expansion from new AI-driven platforms can outpace the cost of debt servicing and potential legal settlements. Investors are left to weigh the promise of a leaner, more profitable medtech giant against the immediate risks of a liquidity crunch or catastrophic legal judgments.

10-QFeb 24, 2026
Expand Sequence

The latest filing presents a company in the midst of a high-stakes transformation. While the spin-off of MiniMed and growth in AI-driven medical technology offer a path toward a valuation re-rating, these catalysts are currently clashing with deteriorating operational margins and a heavy debt burden. The company is effectively racing to monetize its innovation pipeline before the weight of legacy liabilities and cost pressures further erode capital.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.